JP2015529236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529236A5 JP2015529236A5 JP2015532465A JP2015532465A JP2015529236A5 JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5 JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fragment
- region
- protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 51
- 102000018358 immunoglobulin Human genes 0.000 claims 51
- 239000012634 fragment Substances 0.000 claims 42
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000004048 modification Effects 0.000 claims 18
- 238000012986 modification Methods 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 16
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 13
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000833 heterodimer Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229940072221 immunoglobulins Drugs 0.000 claims 10
- 101710120037 Toxin CcdB Proteins 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 101100504121 Mus musculus Ighg gene Proteins 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101001055315 Homo sapiens Immunoglobulin heavy constant alpha 1 Proteins 0.000 claims 2
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 claims 2
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 claims 2
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 2
- 102100026217 Immunoglobulin heavy constant alpha 1 Human genes 0.000 claims 2
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 2
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 claims 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| US61/705,278 | 2012-09-25 | ||
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Division JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Division JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529236A JP2015529236A (ja) | 2015-10-05 |
| JP2015529236A5 true JP2015529236A5 (enExample) | 2016-11-10 |
Family
ID=49237223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532465A Pending JP2015529236A (ja) | 2012-09-25 | 2013-09-25 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (enExample) |
| EP (2) | EP3401337A1 (enExample) |
| JP (5) | JP2015529236A (enExample) |
| KR (1) | KR20150076172A (enExample) |
| CN (1) | CN104968685A (enExample) |
| AU (2) | AU2013322710A1 (enExample) |
| CA (2) | CA3061557A1 (enExample) |
| HK (1) | HK1215950A1 (enExample) |
| IL (2) | IL237872B (enExample) |
| IN (1) | IN2015MN00139A (enExample) |
| WO (1) | WO2014049003A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
| AR085403A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos |
| HK1215950A1 (zh) * | 2012-09-25 | 2016-09-30 | 艾科诺斯科技股份有限公司 | 异源二聚免疫球蛋白的纯化 |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| US11261262B2 (en) * | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| RU2016115866A (ru) | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| WO2015063339A1 (en) * | 2013-11-04 | 2015-05-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| BR112016014969A2 (pt) * | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| ES2973885T3 (es) | 2015-07-09 | 2024-06-24 | Genmab As | Anticuerpos biespecíficos y multiespecíficos y método para aislarlos |
| KR102687212B1 (ko) * | 2015-10-25 | 2024-07-19 | 사노피 | Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질 |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| TN2020000058A1 (en) | 2016-04-13 | 2022-01-06 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| SG11201809620UA (en) * | 2016-05-02 | 2018-11-29 | Hoffmann La Roche | The contorsbody - a single chain target binder |
| US11498977B2 (en) * | 2016-09-29 | 2022-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| CA3043652A1 (en) | 2016-11-18 | 2018-05-24 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| EP3810649A1 (en) * | 2018-06-22 | 2021-04-28 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| CA3105891A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
| CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| MA54601A (fr) | 2018-12-24 | 2022-03-30 | Sanofi Sa | Nouvelles protéines de liaison multi-spécifiques à base de pseudofab |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| EP4141025A4 (en) * | 2019-12-26 | 2024-04-24 | ABL Bio, Inc. | Method for purifying biologically active peptide by using protein a affinity chromatography |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
| US20230242647A1 (en) * | 2020-05-01 | 2023-08-03 | Novartis Ag | Engineered immunoglobulins |
| MX2023004054A (es) | 2020-10-07 | 2023-06-29 | Dren Bio Inc | Anticuerpos anti-dectina 1 y metodos de uso de los mismos. |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| JP2024527262A (ja) | 2021-06-16 | 2024-07-24 | アレクトル エルエルシー | 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法 |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| AU2023285085A1 (en) | 2022-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| CN119497721A (zh) | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| JP2025528751A (ja) | 2022-07-29 | 2025-09-02 | アレクトル エルエルシー | Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法 |
| MX2025002524A (es) * | 2022-09-02 | 2025-06-02 | Zoetis Services Llc | Mutantes de anticuerpos equinos |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026013159A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| WO2026013158A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| US20260113004A1 (en) * | 2024-10-21 | 2026-04-23 | Rgb Systems, Inc. | Class d amplifier with current mode control |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| BRPI0611600B8 (pt) * | 2005-06-17 | 2021-05-25 | Wyeth Corp | método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP4180458A1 (en) * | 2008-10-01 | 2023-05-17 | Amgen Research (Munich) GmbH | Cross-species-specific psma x cd3 bispecific single chain antibody |
| EP2382234A2 (en) | 2008-12-23 | 2011-11-02 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
| JP2012518404A (ja) | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Ｃｄ１９に結合するヒト化抗体及びその使用 |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| LT2975051T (lt) * | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| EP2522724B1 (en) * | 2009-12-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| JP6040148B2 (ja) * | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| AU2012235758B2 (en) | 2011-03-25 | 2015-05-07 | IGI Therapeutics SA | Hetero-dimeric immunoglobulins |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| DK2771364T3 (da) * | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
| CN104137107A (zh) | 2012-03-06 | 2014-11-05 | 福斯分析有限公司 | 用于为化学计量分析形成预测模型的方法、软件和图形用户界面 |
| WO2013136186A2 (en) | 2012-03-13 | 2013-09-19 | Novimmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| HK1215950A1 (zh) * | 2012-09-25 | 2016-09-30 | 艾科诺斯科技股份有限公司 | 异源二聚免疫球蛋白的纯化 |
| WO2015063339A1 (en) * | 2013-11-04 | 2015-05-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2013
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6856610B2 (ja) | ヘテロ二量体免疫グロブリンの精製 | |
| KR102440737B1 (ko) | 이중특이적 항체에 대한 정제 플랫폼 | |
| JP6273219B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP5816170B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2020506898A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| JP2011505810A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2013520984A5 (enExample) | ||
| JP2021530244A5 (enExample) | ||
| JP2021517459A5 (enExample) | ||
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| JP7797203B2 (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| US12545702B2 (en) | Methods for removing undesired components during multistage chromatographic processes | |
| US20260132168A1 (en) | Methods for Removing Undesired Components During Multistage Chromatographic Processes | |
| WO2023137062A1 (en) | Methods for improving resolution of heterodimeric proteins from impurities using affinity chromatography | |
| EA049572B1 (ru) | Способы удаления нежелательных компонентов в многостадийных хроматографических процессах | |
| NZ737843A (en) | Tau-binding antibodies | |
| NZ737843B2 (en) | Tau-binding antibodies | |
| TH143301A (th) | นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies) | |
| NZ774327B2 (en) | Therapeutic antibodies and their uses | |
| NZ724772B2 (en) | ANTIBODIES AGAINST HPA-1a | |
| TH153130A (th) | แอนทิบอดีแอนทิ-TSLP ซึ่งถูกทำวิศวกรรม (Engineered anti-TSLP antibody) |